10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2015 | |||
Consolidated Statement of Income | |||
Period Ending Dec 31, 2015 10-K (Filed: Feb 26, 2016) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |
| Sales | $ 39,498 | 42,237 | 44,033 |
| Costs, Expenses and Other | |||
| Materials and production | 14,934 | 16,768 | 16,954 |
| Marketing and administrative | 10,313 | 11,606 | 11,911 |
| Research and development | 6,704 | 7,180 | 7,503 |
| Restructuring costs | 619 | 1,013 | 1,709 |
| Other (income) expense, net | 1,527 | (11,613) | 411 |
| Total Costs, Expenses and Other | 34,097 | 24,954 | 38,488 |
| Income Before Taxes | 5,401 | 17,283 | 5,545 |
| Taxes on Income | 942 | 5,349 | 1,028 |
| Net Income | 4,459 | 11,934 | 4,517 |
| Less: Net Income Attributable to Noncontrolling Interests | 17 | 14 | 113 |
| Net Income Attributable to Merck & Co., Inc. | 4,442 | 11,920 | 4,404 |
| Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) | 1.58 | 4.12 | 1.49 |
| Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) | 1.56 | 4.07 | 1.47 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2015 | |||
Consolidated Statement of Comprehensive Income | |||
Period Ending Dec 31, 2015 10-K (Filed: Feb 26, 2016) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |
| Net Income Attributable to Merck & Co., Inc. | $ 4,442 | 11,920 | 4,404 |
| Other Comprehensive Income (Loss) Net of Taxes: | |||
| Net unrealized (loss) gain on derivatives, net of reclassifications | (126) | 398 | 229 |
| Net unrealized (loss) gain on investments, net of reclassifications | (70) | 57 | (19) |
| Benefit plan net gain (loss) and prior service credit (cost), net of amortization | 579 | (2,077) | 2,758 |
| Cumulative translation adjustment | (208) | (504) | (483) |
| Other comprehensive income (loss), net of taxes | 175 | (2,126) | 2,485 |
| Comprehensive Income Attributable to Merck & Co., Inc. | 4,617 | 9,794 | 6,889 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2015 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2015 10-K (Filed: Feb 26, 2016) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |
| Cash Flows from Operating Activities | |||
| Net income | $ 4,459 | 11,934 | 4,517 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 6,375 | 6,691 | 6,988 |
| Intangible asset impairment charges | 162 | 1,222 | 765 |
| Foreign currency devaluation related to Venezuela | 876 | 0 | 140 |
| Net charge related to the settlement of Vioxx shareholder class action litigation | 680 | 0 | 0 |
| Gain on divestiture of Merck Consumer Care business | 0 | (11,209) | 0 |
| Gain on AstraZeneca option exercise | 0 | (741) | 0 |
| Loss on extinguishment of debt | 0 | 628 | 0 |
| Equity income from affiliates | (205) | (257) | (404) |
| Dividends and distributions from equity method affiliates | 50 | 185 | 237 |
| Deferred income taxes | (764) | (2,600) | (330) |
| Share-based compensation | 299 | 278 | 276 |
| Other | 757 | (95) | 259 |
| Net changes in assets and liabilities: | |||
| Accounts receivable | (480) | (554) | 436 |
| Inventories | 805 | 79 | (365) |
| Trade accounts payable | (37) | 593 | 522 |
| Accrued and other current liabilities | (8) | 1,635 | (397) |
| Income taxes payable | (266) | (21) | (1,421) |
| Noncurrent liabilities | (277) | 190 | (132) |
| Other | (5) | (98) | 563 |
| Net Cash Provided by Operating Activities | 12,421 | 7,860 | 11,654 |
| Cash Flows from Investing Activities | |||
| Capital expenditures | (1,283) | (1,317) | (1,548) |
| Purchases of securities and other investments | (16,681) | (24,944) | (17,991) |
| Proceeds from sales of securities and other investments | 20,413 | 15,114 | 16,298 |
| Divestiture of Merck Consumer Care business, net of cash divested | 0 | 13,951 | 0 |
| Dispositions of other businesses, net of cash divested | 316 | 1,169 | 46 |
| Proceeds from AstraZeneca option exercise | 0 | 419 | 0 |
| Acquisition of Cubist Pharmaceuticals, Inc., net of cash acquired | (7,598) | 0 | 0 |
| Acquisition of Idenix Pharmaceuticals, Inc., net of cash acquired | 0 | (3,700) | 0 |
| Acquisitions of other businesses, net of cash acquired | (146) | (181) | (246) |
| Acquisition of Bayer AG collaboration rights | 0 | (1,000) | 0 |
| Cash inflows from net investment hedges | 139 | 195 | 350 |
| Other | 82 | (80) | (57) |
| Net Cash Used in Investing Activities | (4,758) | (374) | (3,148) |
| Cash Flows from Financing Activities | |||
| Net change in short-term borrowings | (1,540) | (460) | (159) |
| Payments on debt | (2,906) | (6,617) | (1,775) |
| Proceeds from issuance of debt | 7,938 | 3,146 | 6,467 |
| Purchases of treasury stock | (4,186) | (7,703) | (6,516) |
| Dividends paid to stockholders | (5,117) | (5,170) | (5,157) |
| Other dividends paid | 0 | (77) | (120) |
| Proceeds from exercise of stock options | 485 | 1,560 | 1,210 |
| Other | 56 | 208 | 60 |
| Net Cash Used in Financing Activities | (5,270) | (15,113) | (5,990) |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | (1,310) | (553) | (346) |
| Net Increase (Decrease) in Cash and Cash Equivalents | 1,083 | (8,180) | 2,170 |
| Cash and Cash Equivalents at Beginning of Year | 7,441 | 15,621 | |
| Cash and Cash Equivalents at End of Year | 8,524 | 7,441 | 15,621 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
MERCK & CO., INC. | ||
Ticker: MRK Fiscal Year: 2015 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2015 10-K (Filed: Feb 26, 2016) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2015 | Dec 31, 2014 | |
| Assets | ||
| Current Assets | ||
| Cash and cash equivalents | $ 8,524 | 7,441 |
| Short-term investments | 4,903 | 8,278 |
| Accounts receivable (net of allowance for doubtful accounts of $165 in 2015 and $153 in 2014) (excludes accounts receivable of $10 in 2015 and $80 in 2014 classified in Other assets - see Note 5) | 6,484 | 6,626 |
| Inventories (excludes inventories of $1,569 in 2015 and $1,664 in 2014 classified in Other assets - see Note 6) | 4,700 | 5,571 |
| Other current assets | 5,153 | 4,689 |
| Total current assets | 29,764 | 32,605 |
| Investments | 13,039 | 13,515 |
| Property, Plant and Equipment (at cost) | ||
| Land | 490 | 541 |
| Buildings | 12,154 | 13,101 |
| Machinery, equipment and office furnishings | 14,261 | 16,050 |
| Construction in progress | 1,525 | 1,448 |
| Property, Plant and Equipment, Gross | 28,430 | 31,140 |
| Less: accumulated depreciation | 15,923 | 18,004 |
| Property, Plant and Equipment, Net, Total | 12,507 | 13,136 |
| Goodwill | 17,723 | 12,992 |
| Other Intangibles, Net | 22,602 | 20,386 |
| Other Assets | 6,144 | 5,533 |
| Total Assets | 101,779 | 98,167 |
| Liabilities and Equity | ||
| Current Liabilities | ||
| Loans payable and current portion of long-term debt | 2,585 | 2,704 |
| Trade accounts payable | 2,533 | 2,625 |
| Accrued and other current liabilities | 11,216 | 10,523 |
| Income taxes payable | 1,560 | 1,237 |
| Dividends payable | 1,309 | 1,308 |
| Total current liabilities | 19,203 | 18,397 |
| Long-Term Debt | 23,929 | 18,699 |
| Deferred Income Taxes | 6,535 | 4,467 |
| Other Noncurrent Liabilities | 7,345 | 7,813 |
| Merck & Co., Inc. Stockholders Equity | ||
| Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2015 and 2014 | 1,788 | 1,788 |
| Other paid-in capital | 40,222 | 40,423 |
| Retained earnings | 45,348 | 46,021 |
| Accumulated other comprehensive loss | (4,148) | (4,323) |
| Stockholders' equity before deduction for treasury stock | 83,210 | 83,909 |
| Less treasury stock, at cost: 795,975,449 shares in 2015 and 738,963,326 shares in 2014 | 38,534 | 35,262 |
| Total Merck & Co., Inc. stockholders equity | 44,676 | 48,647 |
| Noncontrolling Interests | 91 | 144 |
| Total equity | 44,767 | 48,791 |
| Total Liabilities and Equity | 101,779 | 98,167 |
| External Links | |
| MERCK & CO., INC. (MRK) Fiscal Year 2015 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |